X0609 4 2026-07-06 0001759425 Mirum Pharmaceuticals, Inc. MIRM 0001197350 BJERKHOLT ERIC false C/O MIRUM PHARMACEUTICALS, INC. 989 E HILLSDALE BLVD., SUITE 300 FOSTER CITY CA 94404 false true false false CHIEF FINANCIAL OFFICER 1 Common Stock 2026-07-06 4 S 0 3124 121.67 D 44057 D Common Stock 2026-07-06 4 S 0 1048 122.43 D 43009 D Common Stock 2026-07-06 4 S 0 528 123.84 D 42481 D Common Stock 2026-07-06 4 S 0 300 124.94 D 42181 D Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. . The weighted average sale price for the transaction reported was $121.67, and the range of prices were between $121.13 and $122.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. . The weighted average sale price for the transaction reported was $122.43, and the range of prices were between $122.235 and $123.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. . The weighted average sale price for the transaction reported was $123.84, and the range of prices were between $123.285 and $124.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. /s/ Judit Ryvkin, Attorney-in-Fact 2026-07-08